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Objective: To study the clinical effect of continuous blood puriﬁcation on acute renal
failure.
Methods: A total of 46 patients with acute renal failure treated with continuous renal
replacement therapy in our hospital from April 2011 to December 2015 were retro-
spectively analyzed. Patients choosing continuous veno-venous hemoﬁltration (CVVH)
mode were collected into CVVH group and patients choosing continuous venovenous
hemodiaﬁltration (CVVHDF) mode were collected into CVVHDF group, and their
general condition, hospitalization conditions and blood biochemical indexes were
analyzed.
Results: Before and after treatment, the voided volumes and APACHE II scores of
patients in CVVHDF group and CVVH group showed no differences. After treatment, the
voided volumes of patients in the two groups were all higher than those before treatment
and their APACHE II scores were all lower than those before treatment. The duration of
continuous renal replacement therapy and the hospital stays in ICU of patients in
CVVHDF group were all shorter than those in CVVH group. In CVVHDF group, the
ratios of mechanical ventilation and death and the total hospitalization time had no sig-
niﬁcant differences with those in CVVH group. After treatment, the contents of blood
urea nitrogen, serum creatinine, uric acid, b2 microglobulin, glutamic-pyruvic trans-
aminase, aspartate transaminase, lactic dehydrogenase and creatine kinase isoenzyme of
patients in CVVHDF group were all lower than those in CVVH group.
Conclusions: Continuous blood puriﬁcation therapy possesses exact curative effect on
acute renal failure. The cleanup effect of CVVHDF mode on solutes and its protective
effect on heart and liver were all superior to those of CVVH mode.1. Introduction
Acute renal failure (ARF) is common in the clinical critical
disease characterized by sharp reduction of glomerular ﬁltration
rate, rapid accumulation of toxic metabolites in body and water-
electrolyte and acid-base imbalance, which is mostly accompa-
nied with multiple organ dysfunction and more likely to induce
multiple organ dysfunction syndrome. These patients have a
poor prognosis and show a higher mortality rate[1,2]. ARF hasalways been a difﬁculty in clinical treatment. Studies have
reported that the mortality rate of ARF is more than 30%. It
has become a heated research problem that how to correct the
continuous renal function damage[3,4]. Severe trauma, massive
blood loss and severe infection are all the common causes for
ARF. The accumulation of toxic metabolites accompanied by
renal function damage is the important part causing multiple
organ function damage. Sweeping the toxic metabolites timely
can improve the disease condition and prognosis[5,6].
Continuous renal replacement therapy (CRRT) is the important
method in clinic to treat ARF, severe pancreatitis and multiple
organ dysfunction and so on. The applied modes of our
country are more likely to choose continuous veno-venous
hemoﬁltration (CVVH), while continuous venovenous hemo-
diaﬁltration (CVVHDF) is popular in abroad[7–9].
At present, the research about the curative effect of the two
CRRT modes (CVVH and CVVHDF) on ARF is insufﬁcient. Innder the CC BY-NC-ND license (http://
Table 1
General clinical data of patients in the two groups.
General clinical data CVVHDF
group
(n = 19)
CVVH
group
(n = 27)
P
Gender (male/female) 11/8 16/11 > 0.05
Age 37.6 ± 7.9 39.1 ± 7.3 > 0.05
Pathogens
Severe pneumonia 6 9 > 0.05
Abdominal trauma complicated
with abdominal cavity infection
3 4 > 0.05
Severe pancreatitis 4 5 > 0.05
Craniocerebral trauma 4 5 > 0.05
Chest trauma 2 4 > 0.05
Table 2
General condition of patients in the two groups before and after treatment.
General condition CVVHDF
group (n = 19)
CVVH group
(n = 27)
P
Voided volume
(mL/day)
Before
treatment
334.2 ± 54.9 328.4 ± 49.5 > 0.05
After
treatment
1704.1 ± 254.8* 1693.4 ± 227.9* > 0.05
APACHE II
score
Before
treatment
18.95 ± 2.96 18.32 ± 2.75 > 0.05
After
treatment
11.33 ± 2.14* 11.81 ± 2.35* > 0.05
*: The comparisons between before treatment and after treatment had
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continuous blood puriﬁcation on treating ARF.
2. Materials and methods
2.1. Clinical data
A total of 46 patients with ARF treated with CRRT in our
hospital from April 2011 to December 2015 were retrospec-
tively analyzed. Inclusion criteria for the cases are as follows:
(1) all patients were consistent with the diagnosis of ARF that
urine volume is less than 20 mL/h persisting for more than 6 h,
diuretic treatment can't increase the urine output and serum
creatinine (Scr) is more than 26.5 mmol/L for 2 or 2 times, or
Scr elevates more than 50% in a short time; (2) the patients
were treated with renal replacement therapy for the ﬁrst time
and the therapeutic regimen was CRRT, which included CVVH
and CVVHDF; (3) the patients were not treated with hormones
and immunosuppressant drug and so on; (4) patients accom-
panied with malignant tumors and autoimmune diseases were
excluded.
2.2. Methods
2.2.1. Continuous blood puriﬁcation therapy method
Femoral vein puncture maintained single-needle double-
lumen catheters was conducted using Seldinger method which
connected Prismaﬂex bedside blood puriﬁcation system to
perform treatment. The time for treatment persisted for 24 h and
the replacement volume and blood ﬂow volume were 80 mg/
(kg$h) and 200 mL/min, respectively. The patients in CVVH
group chose CVVH mode of which the blood ﬁlter was AN69-
M1000 polypropylene eye ﬁlm and displacement liquid was
bicarbonate ﬂuid replacement (5000 mL/bag). The patients in
CVVHDF group chose CVVHDF mode of which the blood ﬁlter
was AV600S polysulfone membrane and the displacement
liquid was identical to that of CVVH group. The displacement
liquid of the two groups was all generated online by hemoﬁl-
tration apparatus with machine, which constituents were Na+
(140 mmol/L), Cl− (103 mmol/L), Ca2+ (1.5 mmol/L), Mg2+
(0.6 mmol/L), K+ (3.5 mmol/L) and HCO3 − (35 mmol/L).
2.2.2. Clinical efﬁcacy evaluation
Medical records of patients in the two groups were analyzed
and information of CRRT duration time, number of mechanical
ventilation, number of death, hospital stays in ICU and total
hospitalization time and so on was collected. At the end of
dialysis before and after treatments, the severity of patient's
condition was evaluated by APACHE II score and 24-h urine
volumes of the patients were record. At day 3 before and after
treatment, serum was collected and the contents of blood urea
nitrogen (BUN), Scr, uric acid (UA), b2 microglobulin (b2-
MG), glutamic-pyruvic transaminase (ALT), aspartate trans-
aminase (AST), lactic dehydrogenase (LDH) and creatine kinase
isoenzyme (CK-MB) were detected by fully automatic
biochemical analyser.
2.2.3. Statistical methods
SPSS19.0 version software was used to input and analyze the
data. Measurement data were expressed as mean ± SD and
analyzed by t-test. Enumeration data were expressed asfrequencies and analyzed by Chi-square. P < 0.05 was the
standard to judge the difference having statistical signiﬁcance.
3. Results
3.1. General clinical data of patients in the two groups
In CVVHDF group, 19 cases included 11 males and 8 fe-
males with the mean age of (37.6 ± 7.9) years. Pathogens were
the follows: 6 cases of severe pneumonia, 3 cases of abdominal
trauma complicated with abdominal cavity infection, 4 cases of
severe pancreatitis, 4 cases of craniocerebral trauma and 2 cases
of chest trauma. In CVVH group, a total of 27 cases included 16
males and 11 females with the mean age of (39.1 ± 7.3) years.
Pathogens were the follows: 9 cases of severe pneumonia, 4
cases of abdominal trauma complicated with abdominal cavity
infection, 5 cases of severe pancreatitis, 5 cases of craniocerebral
trauma and 4 cases of chest trauma. The gender, age and
composition of pathogens of patients in the two groups had no
signiﬁcant difference (Table 1).3.2. General condition of patients in the two groups
before and after treatment
The urine output and APACHE II score of patients in the two
groups before and after treatment were undifferentiated. The
voided volumes of patients in the two groups after treatment was
all more than those before treatment [CVVHDF group:
(334.2 ± 54.9) vs. (1704.1 ± 254.8) mL/day and CVVH group:
(328.4 ± 49.5) vs. (1693.4 ± 227.9) mL/day] and APACHE II
scores was all lower than those before treatment [CVVHDF
group: (18.95 ± 2.96) vs. (11.33 ± 2.14) and CVVH group:
(18.32 ± 2.75) vs. (11.81 ± 2.35)] (Table 2).differences, P < 0.05.
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groups
The duration of CRRT [(3.84 ± 0.69) vs. (5.98 ± 0.81) days]
and the hospital stays in ICU [(4.81 ± 0.77) vs. (7.41 ± 0.95)
days] of patients in CVVHDF group were all shorter than those
in CVVH group. In CVVHDF group, the ratio of mechanical
ventilation (42.11% vs. 44.44%) and death rate (5.30% vs.
7.40%) and total hospitalization time [(20.38 ± 3.96) vs.
(21.13 ± 4.20) days] had no signiﬁcant differences as compared
with those in CVVH group (Table 3).Table 3
Hospitalization condition of patients in the two groups.
Hospitalization
condition
CVVHDF group
(n = 19)
CVVH group
(n = 27)
P
CRRT duration (day) 3.84 ± 0.69 5.98 ± 0.81 < 0.05
Mechanical ventilation
[n (%)]
8 (42.11%) 12 (44.44%) > 0.05
Death [n (%)] 1 (5.30%) 2 (7.40%) > 0.05
Hospital stays in ICU
(day)
4.81 ± 0.77 7.41 ± 0.95 > 0.05
Total hospitalization
time (day)
20.38 ± 3.96 21.13 ± 4.20 > 0.053.4. Blood biochemical indexes of patients in the two
groups before and after treatment
Before treatment, the contents of BUN, Scr, UA, b2-MG,
ALT, AST, LDH, CK-MB of patients in CVVHDF group and
CVVH group had no signiﬁcant differences. The contents of
BUN, Scr, UA, b2-MG, ALT, AST, LDH, CK-MB of pa-
tients in two groups after treatment were all lower than those
before treatment. After treatment, the contents of BUN, Scr,
UA, b2-MG, ALT, AST, LDH, CK-MB of patients in
CVVHDF group were all lower than those in CVVH group
(Table 4).Table 4
Blood biochemical indexes of patients in the two groups.
Blood biochemical indexes CVVHDF gr
BUN (mmol/L) Before treatment 45.49 ±
After treatment 13.58 ±
Scr (mmol/L) Before treatment 993.12 ±
After treatment 352.49 ±
UA (mmol/L) Before treatment 755.29 ±
After treatment 132.43 ±
b2-MG (mg/mL) Before treatment 7.85 ±
After treatment 2.74 ±
ALT (IU/L) Before treatment 442.59 ±
After treatment 157.79 ±
AST (IU/L) Before treatment 552.86 ±
After treatment 193.44 ±
LDH (IU/L) Before treatment 1893.48 ±
After treatment 723.62 ±
CK-MB (IU/L) Before treatment 3354.50 ±
After treatment 552.34 ±
a: The comparisons between before treatment and after treatment had differen
group had differences, P < 0.05.4. Discussion
Severe infections and traumas are the common causes lead-
ing to ARF. The pathogeneses of patients with ARF collected in
this research included severe pneumonia, abdominal trauma
complicated with abdominal cavity infection, severe pancrea-
titis, craniocerebral trauma and chest trauma[10,11]. After the
occurrence of ARF, the accumulation of toxic metabolites in
patients can rapidly lead to multiple organ dysfunctions and
increase the risk of the occurrence of multiple organ
dysfunction syndromes[12,13]. CRRT is the effective method in
clinic to rescue ARF and remove toxic metabolites in body,
which refers to the generic terms of blood puriﬁcation
treatment in vitro persisting less than 12 h speciﬁcally.
Comparing to traditional methods of blood puriﬁcation
therapy, CRRT can remove the excessive moisture, toxic
metabolites and inﬂammatory mediators slowly and
continuously and also can maintain the balance of the internal
environment, the stability of hemodynamics and the
improvement of immune function at the same time[14–16]. The
alternative three kinds of CRRT modes in clinic include
CVVH, continuous venovenous hemodialysis and CVVHDF,
of which the two modes of CVVH and CVVHDF can perform
hemoﬁltration by a convection way having a strong effect to
remove middle and small solutes, and isotonic dehydration is
used in treatment process, and hemodynamics is relatively
stable. Therefore, CVVH and CVVHDF can be more widely
used in emergency rescue and treatment in clinic[17,18].
Convection is the only way that CVVH removes the solutes in
body and also is CRRT mode which is the most widely used in
domestic hospitals[19,20]. CVVHDF also has the convection and
diffusion functions to remove the solutes and has the cleanup
effect on large, middle and small molecules solutes. Therefore,
abroad hospitals are likely to choose CVVHDF mode to
conduct CRRT treatment[21,22]. There is a lack of related
researches on the advantages and disadvantages of CVVH and
CVVHDF modes of CRRT treated on ARF treatment at
present. Clinicians are also lack of corresponding theoretical
guidances choosing CRRT treatment modes. In this research,
we compared the general condition before and after treatment
and found that the voided volumes of patients all signiﬁcantlyoup (n = 19) CVVH group (n = 27) P
9.24 46.31 ± 8.97 > 0.05
2.24a,b 22.18 ± 2.86a < 0.05
187.76 984.52 ± 179.39 > 0.05
85.92a,b 559.27 ± 103.57a < 0.05
129.35 768.14 ± 112.75 > 0.05
20.35a,b 250.39 ± 42.67a < 0.05
1.04 7.72 ± 0.96 > 0.05
0.51a,b 5.51 ± 0.82a < 0.05
76.14 450.21 ± 64.66 > 0.05
24.42a,b 294.34 ± 41.76a < 0.05
81.37 560.24 ± 75.92 > 0.05
22.97a,b 265.61 ± 34.68a < 0.05
335.29 1914.54 ± 294.64 > 0.05
103.51a,b 1135.62 ± 176.37a < 0.05
586.51 3244.29 ± 481.35 > 0.05
103.59a,b 1045.21 ± 177.69a < 0.05
ces, P < 0.05. b: The comparisons between CVVH group and CVVHDF
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APACHE II scores were signiﬁcantly lower and the voided
volumes and APACHE II scores between two treatment modes
showed no differences, which illustrated that two CRRT modes
can improve the general condition of patients effectively and
the ﬁnal treatment outcome had no signiﬁcant differences. The
further analysis of the treatment process showed that CRRT
duration and hospital stays in ICU are shorter in patients of
CVVHDF group. The ratios of mechanical ventilation and
death and the total hospitalization time had no signiﬁcant
differences as compared with CVVH mode treatment, which
indicated that though the ﬁnal treatment outcome of two CRRT
modes had no signiﬁcant difference, CVVHDF mode had a
higher cleaning efﬁciency and can shorten the time of CRRT
treatment and hospital stay in ICU.
The CVVH and CVVHDF modes can remove the solutes in
body through the convection way, but CVVHDF also has the
function to remove solutes by a diffusion method like the
continuous venovenous hemodialysis-mode. Hence, it has a
higher efﬁciency on cleaning up solutes than CVVH mode and
meanwhile possesses the removal effect on large, middle and
small molecule solutes[17,23,24]. If the creatinine, urea nitrogen and
UA are the representatives of small molecule solutes, b2-MG is
the representative of small molecule solute[25,26]. At day 3 after
treatment, the contents of BUN, Scr, UA and b2-MG of pa-
tients in CVVHDF group were signiﬁcant lower than those in
CVVH group, which indicated that CVVHDF mode had a
stronger capacity to remove middle and small molecule solutes.
The accumulation of toxic metabolites in body can produce
cardiotoxicity and hepatotoxicity leading to cell rupture and
inducing a variety of molecules in endochylema such as ALT,
AST, LDH and CK-MB to release into blood circulation[27–29].
The contents of serum ALT, AST, LDH and CK-MB are used
to reﬂect the damage of myocardial cells and hepatic cells. We
analyzed the degree of myocardial cell and hepatic cell damage
on the patients after ARF treatment and the results showed that
the contents of ALT, AST, LDH and CK-MB of patients in
CVVHDF group were signiﬁcant lower than those in CVVH
group at day 3 after treatment, which conﬁrmed that CVVHDF
mode can protect myocardial cells and hepatic cells from dam-
age based on removing middle and small molecule solutes so as
to prevent the occurrence of multiple organ dysfunctions.
In conclusion, continuous blood puriﬁcation therapy pos-
sesses exact curative effect on ARF. The cleanup effect on
solutes and protective effect on heart and liver of CVVHDF
mode are all superior to CVVH mode.
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